| Literature DB >> 35458701 |
Wenfeng Wu1, Zhuxian Wang1, Yufan Wu1, Huiyi Wu2, Tingting Chen1, Yaqi Xue1, Yuan Wang1, Cuiping Jiang1, Chunyan Shen1, Li Liu1, Hongxia Zhu3, Qiang Liu1.
Abstract
Keratin liposomes have emerged as a useful topical drug delivery system given theirenhanced ability to penetrate the skin, making them ideal as topical drug vehicles. However, the mechanisms of the drug penetration enhancement of keratin liposomes have not been clearly elucidated. Therefore, licochalcone A(LA)-loaded skin keratin liposomes (LALs) were prepared to investigate their mechanisms of penetration enhancement on the skin and inB16F10 cells. Skin deposition studies, differential scanning calorimetry (DSC), attenuated total reflection-Fourier Transform Infrared Spectroscopy (ATR-FTIR), and skin distribution and intracellular distribution studies were carried out to demonstrate the drug enhancement mechanisms of LALs. We found that the optimal application of LALs enhanced drug permeation via alterations in the components, structure, and thermodynamic properties of the stratum corneum (SC), that is, by enhancing the lipid fluidization, altering the skin keratin, and changing the thermodynamic properties of the SC. Moreover, hair follicles were the main penetration pathways for the LA delivery, which occurred in a time-dependent manner. In the B16F10 cells, the skin keratin liposomes effectively delivered LA into the cytoplasm without cytotoxicity. Thus, LAL nanoparticles are promising topical drug delivery systems for pharmaceutical and cosmetic applications.Entities:
Keywords: Licochalcone A; lipid nanoparticles; mechanisms of penetration enhancement; topical drug delivery system
Mesh:
Substances:
Year: 2022 PMID: 35458701 PMCID: PMC9029797 DOI: 10.3390/molecules27082504
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1TEM micrographs of LAL nanoparticles.
Figure 2(a) The release profile of LA-loaded skin keratin liposomes over48 h (n = 3); (b) the skin retention of LAL nanoparticles and free LA at 2, 4, 8, and 12 h (* p < 0.05, ** p < 0.01 vs. LA, n = 3).
Figure 3(a) FTIR spectra of skin samples treated with different formulations; (b) the DSC thermograms of skin samples after treatment with LALs and other formulations.
Peaks of SC lipids and keratin of skin samples after treatment with different formulations.
| Sample | Lipids | Keratin | Keratin | |||
|---|---|---|---|---|---|---|
| VasCH2 | VsCH2 | Amide I | Amide II | Melting Temperature (°C) | Enthaly (J/g) | |
| LA | 2923.12 | 2856.22 | 1585.93 | 1531.20 | 120.71 | 322.13 |
| LAL | 2928.43 | 2859.27 | 1584.04 | 1535.92 | 115.24 | 351.60 |
| NL | 2925.68 | 2856.14 | 1577.66 | 1542.62 | 111.65 | 336.78 |
| CT | 2922.36 | 2858.31 | 1588.15 | 1518.49 | 118.96 | 335.39 |
Figure 4(a) The fluorescence images of the skin samples treated with C6 and C6L for 10, 20, 30, 40, 50, and 60 min. The scale bar is 100 μm; (b) the quantitative florescence intensities of C6 and C6L into skin at different time (** p < 0.01 vs. C6, n = 3).
Figure 5B16F10 cell viability after treatment with LAL, LF, and NL formulations for 24 h (n = 6).
Figure 6Intracellular distribution of free C6 and C6L micelles in B16F10 cells (scale bar: 10 μm).
Figure 7Photograph of the abdomens of guinea pigs exposed to the various formulations.
Skin irritation.
| Occurrence Rate (%) | Level | Strength | Skin Irritation Definition |
|---|---|---|---|
| 0–8 | I | None | No erythema and no hydroderma |
| 9–28 | II | Mild | Mild erythema and mild hydroderma (barely visible) |
| 29–64 | III | Moderate | Moderate erythema and moderate hydroderma (obviously raised) |
| 65–80 | IV | Severe | Severe erythema and severe hydroderma (the skin humps 1 mm with the outline clear) |
| 81–100 | V | Extreme | Purplish red erythema or mild eschar hydroderma, extreme hydroderma (skin humps of more than 1 mm with the outline expansile) |